|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: -9.54%|
|Previous Close: $47.52|
|52 Week Range: $37.11 - $56.73|
|Oustanding Shares: 27,635,851|
|Market Cap: 1,313,255,640|
|Qtr (04/13)||Qtr (07/13)||FY (04/13)||FY (04/14)|
|Number of Analysts||5||5||6||5|
|Growth Rate (Year over Year)||11.58%||17.89%||33.99%||13.18%|
CYBX was upgraded to Buy, Lazard Capital Market said. A proprietary survey showed that sales reps were not using inappropriate sales tactics, making the recent pullback a buying opportunity. Estimates through 2014 were raised, $57 price target.
Shares of CYBX now seen reaching $57, Canaccord said. Estimates also raised on a record quarter. Buy rating.
CYBX was upgraded from Hold to Buy, Canaccord Genuity said. $56 price target. Company continues to execute well and depression treatment should drive near-term growth.
I’m making trades in Movado and Sanderson Farms but passing on Cyberonics and PVH.
There are four reports coming up I find interesting.
Contributor Ken Shreve takes a look at upcoming economic data and some key earnings reports for the week of Aug. 27
These promising medical-device names aren’t on the S&P, but they deserve plenty of attention.
Shares of CYBX now seen reaching $58, Jefferies said. Estimates also raised on Chance of reversing coverage policy. Buy rating.
Contributor Ken Shreve takes a look at a light week of economic data and some earnings reports for the week of June 4